SV News
- 9 September 2024SV NewsNeurology’s human data revolution
- 9 September 2024SV NewsEyes on the target: Drug discovery’s new paradigm
3 September 2024Portfolio NewsPrilenia’s Pridopidine for Huntington’s Disease Accepted for European Marketing Authorisation Review
3 September 2024Portfolio NewsAmphista Therapeutics appoints Antony Mattessich as Chief Executive Officer
28 August 2024Portfolio NewsMestag Therapeutics Awarded Significant Grant from Innovate UK’s Prestigious Cancer Therapeutics Program to Accelerate the Path to the Clinic for MST-0300
30 July 2024Portfolio NewsMontara Therapeutics Closes $8 Million Seed Round Led by SV Health Investors’ Dementia Discovery Fund and Two Bear Capital to Develop Safer, More Effective Neuroscience Drugs Using a Novel Brain-Only Pharmacology Approach
29 July 2024Portfolio NewsBioAge Announces First Patient Dosed in the STRIDES Phase 2 Clinical Trial Evaluating Azelaprag as a Novel Treatment for Obesity in Combination with Tirzepatide
24 July 2024Portfolio NewsTransposon Announces Final Results from a Phase 2 Study of TPN-101 for the Treatment of C9orf72-Related Amyotrophic Lateral Sclerosis and/or Frontotemporal Dementia- 12 July 2024SV NewsUK needs Covid-style push on dementia drugs, says ex-head of vaccine taskforce
10 July 2024Portfolio NewsQuell Therapeutics Appoints Experienced Biopharma Leader Luke Beshar as Independent Chair of its Board of Directors
2 July 2024Portfolio NewsASPIRE-FTD Phase 1/2 Clinical Trial Opens in the U.S. at The Ohio State University Wexner Medical Center
2 July 2024Portfolio NewsSteven James, Accomplished CEO and Biotech Executive, Joins Board of Directors of Rondo Therapeutics
